Hemington Wealth Management raised its position in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 44.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,310 shares of the company’s stock after buying an additional 404 shares during the period. Hemington Wealth Management’s holdings in ARK Genomic Revolution ETF were worth $30,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also modified their holdings of ARKG. Sanctuary Advisors LLC purchased a new position in shares of ARK Genomic Revolution ETF during the second quarter worth $222,000. Summit Investment Advisory Services LLC purchased a new position in ARK Genomic Revolution ETF in the third quarter valued at $417,000. Crescent Grove Advisors LLC boosted its holdings in ARK Genomic Revolution ETF by 1.6% in the third quarter. Crescent Grove Advisors LLC now owns 28,914 shares of the company’s stock valued at $740,000 after purchasing an additional 460 shares during the period. Prospera Financial Services Inc boosted its holdings in ARK Genomic Revolution ETF by 18.2% in the third quarter. Prospera Financial Services Inc now owns 33,607 shares of the company’s stock valued at $860,000 after purchasing an additional 5,180 shares during the period. Finally, Captrust Financial Advisors purchased a new position in ARK Genomic Revolution ETF in the third quarter valued at $485,000.
ARK Genomic Revolution ETF Stock Up 17.2 %
BATS:ARKG opened at $27.67 on Friday. The company has a 50-day moving average of $25.48 and a two-hundred day moving average of $25.24.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
See Also
- Five stocks we like better than ARK Genomic Revolution ETF
- Insider Buying Explained: What Investors Need to Know
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
